Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation.
Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation.
复制标题
DOI：
10.3389/fimmu.2021.715909
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Cao X
中科院分区：
文献类型：
--
作者：
Lutfi F;Wu L;Sunshine S;Cao X
免疫检查点抑制剂疗法和同种异体造血细胞移植（alloHCT）代表了两种不同的模式，为各种恶性肿瘤的长期治愈提供了机会，近年来取得了许多突破。在此，我们综述了CD 27-CD 70共刺激通路及其治疗潜力：1）与检查点抑制剂和其他免疫疗法联合使用; 2）其作为预防移植物抗宿主病（GVHD）的新方法的潜在能力。我们进一步回顾了GVHD作为供体和宿主免疫系统之间的复杂免疫现象的最新进展，特别是在混合嵌合体的早期阶段，以及预防GVHD发展的潜在新治疗方法。
Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-versus-host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.
DOI：
10.4049/jimmunol.1502181
发表时间：
2017-07-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Leigh ND;O'Neill RE;Du W;Chen C;Qiu J;Ashwell JD;McCarthy PL;Chen GL;Cao X
通讯作者：
Cao X